Evidence map›Paper›PMID 30083957›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2020

Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.

Karin Gmitterová, Joanna Gawinecka, Franc Llorens, Daniela Varges, Peter Valkovič, Inga Zerr

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Tau: a biomarker of Huntington's disease.Molecular psychiatry · 2023
    Review
  8. Review
  9. Article
  10. Tau in the Pathophysiology of Parkinson's Disease.Journal of molecular neuroscience : MN · 2021
    Review
  11. Alteration in cerebrospinal fluid (CSF) markers associated with α-synucleinopathies.European archives of psychiatry and clinical neuroscience · 2021
    Article
  12. Review
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Karin GmitterováDepartment of Neurology, Clinical Dementia Center and DZNE, National TSE Reference Centre, University Medical School, Georg-August University, Robert-Koch-Str. 40, 37073, Göttingen, Germany.
Joanna GawineckaDepartment of Neurology, Clinical Dementia Center and DZNE, National TSE Reference Centre, University Medical School, Georg-August University, Robert-Koch-Str. 40, 37073, Göttingen, Germany.
Franc LlorensDepartment of Neurology, Clinical Dementia Center and DZNE, National TSE Reference Centre, University Medical School, Georg-August University, Robert-Koch-Str. 40, 37073, Göttingen, Germany.
Daniela VargesDepartment of Neurology, Clinical Dementia Center and DZNE, National TSE Reference Centre, University Medical School, Georg-August University, Robert-Koch-Str. 40, 37073, Göttingen, Germany.
Peter ValkovičSecond Department of Neurology, Comenius University, Bratislava, Slovakia.ORCID http://orcid.org/0000-0001-7837-8781
Inga ZerrDepartment of Neurology, Clinical Dementia Center and DZNE, National TSE Reference Centre, University Medical School, Georg-August University, Robert-Koch-Str. 40, 37073, Göttingen, Germany. epicjd@med.uni-goettingen.de.ORCID http://orcid.org/0000-0002-6722-2463
University of Göttingen · DEComenius University Bratislava · SKUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) share a couple of clinical similarities that is often a source of diagnostic pitfalls. We evaluated the discriminatory potential of brain-derived CSF markers [tau, p-tau (181P), Aβ

Indexed as

AgedAged, 80 and overAmyloid beta-PeptidesCohort StudiesDiagnosis, DifferentialDisease ProgressionFemaleHumansLewy Body DiseaseMaleMiddle AgedParkinson DiseasePeptide FragmentsSeverity of Illness Indextau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide Fragmentstau ProteinsCerebrospinal fluidLewy body dementiaNeuron-specific enolaseParkinson’s disease dementiaProtein S100BTau protein

Identifiers

PMID30083957
OpenAlexW2886273621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.